Press Releases

November 12, 2021

Regulatory

Interim report Q3 2021

September 24, 2021

Regulatory

SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis

August 27, 2021

Regulatory

SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)

August 27, 2021

Regulatory

SynAct Pharma: Interim Report January-June 2021 August 27, 2021

August 27, 2021

Regulatory

SynAct Pharma Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis

August 25, 2021

Regulatory

SynAct strengthens IP portfolio – Grant of key European patent covering AP1189

August 20, 2021

Regulatory

SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021

August 6, 2021

Regulatory

SynAct Pharma strengthens its organization with two key recruitments

July 7, 2021

Regulatory

SynAct Pharma Appoints Anders Dyhr Toft, MD, Ph.D., as Chief Medical Officer

July 7, 2021

Regulatory

SynAct Pharma AB Announces Additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients and Reminds of Management Call to Discuss Results

July 2, 2021

Regulatory

SynAct Pharma Hosts Conference Call on Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients

June 30, 2021

Regulatory

SynAct Pharma AB Announces Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients

June 23, 2021

Regulatory

SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations

June 1, 2021

Regulatory

SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients

May 21, 2021

Regulatory

Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021

May 21, 2021

Regulatory

Synact Pharma to present at upcoming investor conference

May 14, 2021

Regulatory

SynAct Pharma AB: SynAct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.

May 12, 2021

Regulatory

SynAct Pharma partners with Örebro University to study cardiovascular disease

May 5, 2021

Regulatory

SynAct Pharma: Interim report January-March 2021

May 4, 2021

Regulatory

SynAct Pharma Board and Management extend lock-up period   UK Version

May 4, 2021

Regulatory

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version

April 30, 2021

Regulatory

SynAct Pharma to participate at Kempen’s virtual Life Sciences Conference

April 19, 2021

Regulatory

SynAct Pharma shareholders propose Marina Bozilenko as new board member

April 19, 2021

Regulatory

Notice of annual general meeting in SynAct Pharma AB

April 13, 2021

Regulatory

SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version

March 18, 2021

Regulatory

SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version

March 1, 2021

Regulatory

SynAct Pharma’s CFO and board member sell shares to cover taxes on holdings

February 11, 2021

Regulatory

SynAct Pharma Names James Knight as Chief Business Officer – Already published in Swedish today

February 5, 2021

Regulatory

SynAct carries out a directed share issue and raises proceeds of SEK 80 million

February 4, 2021

Regulatory

SynAct explores the conditions for carrying out a directed share issue – English version – Published today 17.31 CET

February 4, 2021

Regulatory

SynAct Pharma prepares move to Nasdaq Stockholm – English version – Published today at 17.31 CET

January 26, 2021

Regulatory

SynAct Pharma names Thomas Boesen as Chief Operating Officer

January 11, 2021

Regulatory

Published in English – already published 11:18 CET today Disclosure notice in SynAct Pharma AB